BioLineRx In-Licenses Biokine Novel, Phase II Ready Drug BKT140 for the Treatment of Leukemia, Other Hematological Cancers, and stem cell mobilization.
Biokine is seeking continued funding for this project through collaboration and private and public investments.
BKT170- CXCR4 antagonist for the treatment of skin conditions.
Biokine will seek a co-development partner on this project.
BKT130- Promiscuous chemokine antagonist for age related macular degeneration (AMD).